AACR Annual Meeting 2021: AnchorDx Unveils High-Performance Blood Test for Gastric Cancer Screening
b"GUANGZHOU,China, April 19, 2021 /PRNewswire/ -- At this year's American Association for Cancer Research (AACR) Annual Meeting 2021 (April 10-15), molecular diagnostic company AnchorDx presented a poster (Poster 2610) unveiling its Aurora 2.0 study results.
- b"GUANGZHOU,China, April 19, 2021 /PRNewswire/ -- At this year's American Association for Cancer Research (AACR) Annual Meeting 2021 (April 10-15), molecular diagnostic company AnchorDx presented a poster (Poster 2610) unveiling its Aurora 2.0 study results.
- In addition to superior sensitivity and specificity features, Aurora 2.0 retains its original advantages such as low cost and short turnaround time.
- In China, the incidence and mortality of gastric cancer rank second (10.5%) and third (12.4%), respectively.
- In addition, AnchorDxhas a proprietarybig data and artificial intelligence platform designed for early lung cancer screening, diagnosis, and treatment.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/aacr-annual-meeting-2021-anchord...\n"